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Introduction {#sec1}
============

Cancer kills approximately 8 million people annually (World Health Organization fact sheet number 297). Although anti-cancer therapy is rapidly improving, further therapeutic development is urgently needed. The idea that subpopulations of cells within the tumor mass, cancer stem cells (CSCs) (or tumor-initiating cells), have high tumorigenic and self-renewal ability was proposed more than 20 years ago ([@bib21], [@bib29], [@bib52]). Since then, CSCs have been identified in several human tumors (e.g., leukemia, breast, brain, prostate, colon, and pancreatic cancers), and the notion of eradicating cancer by eroding the CSC pool has started to show potential in humans ([@bib21], [@bib29], [@bib32]). Despite the fact that significant efforts aimed at identifying molecular targets to hinder cancer stemness have been made, these anti-CSCs targets remain poorly understood.

The roles of epigenetic changes (e.g., histone modifications) on cancer behavior and stemness are appreciated. For example, it has recently been shown that protein kinase A indirectly affects histone methylation and expression of epithelial genes, an effect that hinders CSC activity and promotes tumor differentiation, a feature associated with better prognosis ([@bib30]). The histone deacetylase SIRT6 has been suggested to affect tumor behavior as (1) *Sirt6* loss of function facilitates progression of cancer in mice ([@bib20], [@bib40]), (2) *Sirt6* loss-of-function mutations have been found in human cancers ([@bib19]), and (3) SIRT6 expression in tumor lesions positively correlates with survival of cancer patients ([@bib40], [@bib47]). Although these loss-of-function results suggest that SIRT6 is a tumor suppressor, others have shown opposite outcomes ([@bib28]). Whether enhanced SIRT6 function obstructs tumor progression and/or CSCs is unclear.

In this study, we assessed the outcomes of enhanced SIRT6 action in different human and murine cancers. Surprisingly, we found that mutations leading to PI3K activation predict responsiveness to the anti-cancer-stemness action of SIRT6 overexpression.

Results {#sec2}
=======

Differential Responsiveness of Human Cancer Cells to Enhanced SIRT6 Action {#sec2.1}
--------------------------------------------------------------------------

To determine the effect of enhanced SIRT6 expression on tumor biology, six different cancer cells obtained from breast (MDA-MB-231, MCF7, and MCF10DCIS), lung (H1650 and A549), and colorectal (DLD-1) human tumors were transduced with either a control vector or a vector expressing SIRT6. As expected, the latter showed increased SIRT6 protein content compared to controls ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Surprisingly only DLD-1 and MCF7 cells displayed reduced proliferation upon SIRT6 overexpression ([Figure 1](#fig1){ref-type="fig"}A). Because SIRT6 overexpression has been shown to cause apoptosis in cancer cells (including MDA-MB-231 cells) ([@bib51]), we investigated whether changes in apoptosis could underlie the anti-proliferative action of SIRT6 overexpression. Although enhanced SIRT6 expression caused variegate effects on the cell-cycle phases, it was not accompanied by induction of apoptosis because (1) the percentage of the SubG~0~ population and (2) the level of apoptosis markers cleaved caspase 3 and PARP1 were not significantly different between cells overexpressing SIRT6 and their controls ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). We suggest that the discrepancy between our results and the ones reported by Van Meter and colleagues is due to the different approaches (transient transfection \[[@bib51]\] versus stable transfection \[this study\]) used to induce SIRT6 overexpression.

When the ability to form tumorsphere in three-dimensional cultures, which is an established readout of CSCs ([@bib7], [@bib31], [@bib35]), was assessed, we found that SIRT6 overexpression drastically decreases tumorsphere-forming capacity of MCF10DCIS, MCF7, H1650, and DLD-1 cells, while it causes no changes in MDA-MB-231 or A549 cells ([Figure 1](#fig1){ref-type="fig"}B). To independently assess cancer stemness, the size of the cell population with high aldehyde dehydrogenase (ALDH) activity was measured ([@bib5], [@bib6], [@bib8]). This parameter was found to be reduced in H1650 and MCF10DCIS cells ([Figure S1](#mmc1){ref-type="supplementary-material"}D). To directly test whether cancer cells with high ALDH activity (ALDH^high^) represented in [Figure S1](#mmc1){ref-type="supplementary-material"}D are enriched in CSCs, we compared their tumorsphere-forming capacity with the one of cells with low ALDH activity (ALDH^low^). In agreement with previous reports ([@bib8], [@bib24], [@bib53]), ALDH^high^ cells gave rise to a higher number of tumorspheres compared to ALDH^low^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}E), hence supporting that ALDH^high^ cells are enriched in CSCs. Collectively, our data indicate that cancer cells could be categorized into two groups: SIRT6-sensitive cells, which show significant reduction in their stem-like trait (MCF10DCIS, MCF7, H1650, and DLD-1) and SIRT6-insensitive cells (MDA-MB-231 and A549) whose stem-like trait is unaffected by SIRT6 overexpression.

Reduced number of CSCs should lead to reduced tumorigenic capacity in vivo. To test this possibility, SIRT6-sensitive (H1650 and MCF10DCIS) and SIRT6-insensitive (MDA-MB-231) cells were injected into the flank of non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice and their growth was monitored over time. Results shown in [Figure 1](#fig1){ref-type="fig"}C demonstrate that while SIRT6 overexpression does not affect appearance of SIRT6-insensitive MDA-MB-231 xenografts it significantly delays this parameter of SIRT6-sensitive H1650 and MCF10DCIS xenografts. Hence, our data suggest that enhanced SIRT6 expression hinders stemness and tumorigenic capacity of specific human cancer cells.

By surveying the mutations characterizing SIRT6-sensitive and -insensitive cells, we found that SIRT6-sensitive cells bear mutations in genes regulating PI3K signaling while SIRT6-insensitive cells do not. Specifically, MCF10DCIS and MCF7 and DLD-1 cells bear an activating mutation (H1047R and E545K, respectively) in *PIK3CA* gene ([@bib15], [@bib37], [@bib43]). Also, H1650 cells are characterized by *PTEN* (phosphate and tensin homolog deleted on chromosome 10) loss ([@bib42]) ([Figure 1](#fig1){ref-type="fig"}D). On the other hand, MDA-MB-231 and A549 cells are not known to have PI3K activating mutations ([@bib15], [@bib34]) ([Figure 1](#fig1){ref-type="fig"}D). In keeping with their genetic types, phosphorylation status of serine 473 of AKT (P-S473-AKT), which is an established marker of PI3K signaling, was enhanced in SIRT6-sensitive cells; yet, SIRT6 overexpression did not affect, or only marginally affected (e.g., DLD-1 cells), AKT phosphorylation suggesting that it does not influence PI3K signaling at the AKT level ([Figure S1](#mmc1){ref-type="supplementary-material"}A). In summary, our data indicate that the anti-tumor action of SIRT6 overexpression is favored in the context of PI3K activation.

Enhanced SIRT6 Hinders Progression of Breast Cancer with PI3K Activation in Mice {#sec2.2}
--------------------------------------------------------------------------------

Suppression of the CSCs pool is predicted to hinder progression toward high-grade lesions and promote tumor differentiation, a characteristic associated with better prognosis ([@bib30]). The transgenic mouse expressing polyomavirus middle T oncogene (PyMT) under the mouse mammary tumor virus promoter is an established animal model mimicking progression of human breast cancers originating from hyperplastic lesions to high-grade carcinomas; also, these tumors display PI3K activation ([@bib9], [@bib22]) ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Thus, to assess whether enhanced SIRT6 affects stemness and progression of a breast tumor with PI3K activation we crossed genetically engineered mice overexpressing functionally competent SIRT6 protein (Sirt6BAC mice) ([@bib1]) to PyMT mice. Tumor lesions of mice carrying both PyMT and Sirt6BAC alleles (PyMT/Sirt6 mice) were assessed for SIRT6 expression. Data shown in [Figures 2](#fig2){ref-type="fig"}A and 2B indicate that tumors from PyMT/Sirt6 mice have enhanced SIRT6 expression compared to their controls bearing only the PyMT allele. Of note, Sirt6BAC allele had no effect on expression of the oncogene driving tumorigenesis in this cancer model as PyMT mRNA level is similar between groups ([Figure 2](#fig2){ref-type="fig"}C). Due to its histone deacetylase activity, SIRT6 overexpression is expected to dampen expression of its target genes. Indeed, gene set enrichment analysis ([@bib44]) of whole-genome microarray data showed that mRNA levels of several SIRT6's target genes ([@bib17]) are reduced in tumors of PyMT/Sirt6 mice compared to controls ([Figure 2](#fig2){ref-type="fig"}D). Noteworthy, a number of mRNA changes identified by microarray assay were confirmed by real-time qPCR analysis ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Collectively, these results demonstrate that the Sirt6BAC allele brings about enhanced SIRT6 expression and activity in PyMT-driven breast tumors in mice.

To test the consequence of increased SIRT6 function on this cancer model, we analyzed several tumor parameters. PyMT/Sirt6 mice displayed a delay in tumor appearance ([Figure S2](#mmc1){ref-type="supplementary-material"}E). At 12 weeks of age, tumor volume, weight, and number were all found to be reduced in PyMT/Sirt6 compared to controls ([Figure 2](#fig2){ref-type="fig"}E). Tumor growth rate, assessed by tumor diameter evolution after its detection, was also found to be significantly reduced in PyMT/Sirt6 mice ([Figure 2](#fig2){ref-type="fig"}F). To better understand this anti-tumor action of SIRT6 overexpression, we performed histological analyses. In keeping with our in vitro results shown in [Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C, TUNEL assay indicated that altered apoptotic rate is unlikely to be involved because the portion of TUNEL-positive cells in tumor samples was similar between groups ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Notably, while the percentage of necrotic, hyperplastic, or adenomatous-like area (low-grade tumor) was unchanged, the carcinomatous area, which represents the more aggressive/high-grade tumor lesion, was reduced nearly by a factor of two in tumors of PyMT/Sirt6 mice compared to controls ([Figure 2](#fig2){ref-type="fig"}G). These results indicate that enhanced SIRT6 expression/activity keeps this breast cancer model more differentiated, a characteristic associated with better prognosis ([@bib30]). In line with this notion, several genes typically expressed by differentiated mammary gland epithelia were found to be overexpressed in tumors of PyMT/Sirt6 mice compared to controls ([Figures 2](#fig2){ref-type="fig"}H and [S2](#mmc1){ref-type="supplementary-material"}G). Together, our data demonstrate that enhanced SIRT6 function inhibits growth and promotes differentiation of a breast cancer model with PI3K activation.

Enhanced SIRT6 Rearranges Metabolism and Suppresses PI3K Signaling and Stem-like Traits in Breast Tumors {#sec2.3}
--------------------------------------------------------------------------------------------------------

To understand the mechanisms underlying the anti-tumor action of SIRT6 overexpression, we performed metabolomic and transcriptomic analyses. By comparing our transcriptomic data with 246 publicly available microarray datasets including embryonic stem cells (ESCs), adult stem cells (ASCs), induced pluripotent stem (iPS) cells, and terminally differentiated tissues (TDTs) ([@bib3], [@bib26], [@bib27], [@bib36], [@bib39], [@bib48], [@bib49]), we found that genes downregulated in tumors of PyMT/Sirt6 mice ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [Table S1](#mmc2){ref-type="supplementary-material"}) are enriched in stem cells (ESC, iPS cells, and ASCs) ([Figure 3](#fig3){ref-type="fig"}A). Also, we analyzed the enrichment of genes on microarray datasets of human breast cancers ([@bib50]). These samples were classified in normal-like, basal-like, HER2, Claudin-low, and luminal subtypes according to previous reports ([@bib41]). Our results indicated that the genes downregulated in tumors of PyMT/Sirt6 mice are enriched in basal-like/Claudin-low tumors ([Figure 3](#fig3){ref-type="fig"}B), which represent the most stem-like/aggressive breast cancer types ([@bib4], [@bib41]). To independently test whether SIRT6 overexpression hinder stemness of PyMT-driven breast tumors, we measured ALDH expression and enzymatic activity and found these parameters to be lowered in tumors of PyMT/Sirt6 mice ([Figures 3](#fig3){ref-type="fig"}C, [S3](#mmc1){ref-type="supplementary-material"}B, and S3C). We also found that expression of several genes induced by PI3K signaling is downregulated in tumors of PyMT/Sirt6 mice ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}D). However SIRT6 overexpression did not affect PI3K signaling at the AKT level as the status of AKT phosphorylation was similar in tumors from PyMT/Sirt6 mice and their controls ([Figure S2](#mmc1){ref-type="supplementary-material"}B). These results are in keeping with our in vitro results shown in [Figure S1](#mmc1){ref-type="supplementary-material"}A and suggest that the effect of SIRT6 overexpression on PI3K signaling is downstream of AKT phosphorylation.

Next, we performed a metabolomic assay and found that, while only eight out of 313 biochemicals analyzed display significant changes between groups ([Figure S3](#mmc1){ref-type="supplementary-material"}E; [Table S2](#mmc3){ref-type="supplementary-material"}), pathway analysis indicated that the contents of several intermediate metabolites of glycolysis and the pentose phosphate (PPP) pathways, both of which are boosted by PI3K signaling ([@bib25], [@bib45]), are lowered in tumors of PyMT/Sirt6 mice compared to controls ([Figure 3](#fig3){ref-type="fig"}E). Collectively, our data suggest that enhanced SIRT6 expression exerts anti-tumor action by rearranging metabolism, suppressing PI3K signaling downstream of AKT, and by hindering cancer stem-like attributes of tumors with PI3K activation.

PI3K Activation Is Required for Anti-cancer Stemness Action of SIRT6 Overexpression {#sec2.4}
-----------------------------------------------------------------------------------

To further determine the mechanisms underlying anti-tumor action of SIRT6 overexpression, we focused on PI3K activation as it correlates with responsiveness to SIRT6 overexpression. To directly test whether PI3K activation is required for the anti-tumor action of SIRT6 overexpression, two cell lines derived from DLD-1 cells were transduced with either a control vector or a vector expressing SIRT6. As expected, the latter displayed increased SIRT6 compared to controls ([Figure S4](#mmc1){ref-type="supplementary-material"}A). These genetically modified clones are isogenic except that one bears a wild-type allele (DLD-1-WT), while the other bears the E545K *PIK3CA* allele (DLD-1-MT) ([@bib37]). In keeping with their genetic types, P-S473-AKT/AKT ratio was enhanced in DLD-1-MT compared to DLD-1-WT cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). In keeping with data shown in [Figures S1](#mmc1){ref-type="supplementary-material"}A and [S2](#mmc1){ref-type="supplementary-material"}A, SIRT6 overexpression did not suppress P-S473-AKT/AKT ratio also in DLD-1-WT and DLD-1-MT cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Similar to the effects observed in parental DLD-1 cells, SIRT6 overexpression significantly diminished tumorsphere-forming capacity of DLD-1-MT cells and appearance of DLD-1-MT xenografts ([Figures 4](#fig4){ref-type="fig"}A and 4B). However, SIRT6 overexpression was not able to affect these parameters in DLD-1-WT cells and xenografts ([Figures 4](#fig4){ref-type="fig"}A and 4B). Together, these results demonstrate that the presence of a PI3K activating mutation is required for the anti-cancer-stemness and -tumor-forming ability of SIRT6 overexpression.

By surveying our transcriptomic and metabolomic data, we noticed that contents of genes and intermediates of the PPP and lipid metabolism (e.g., 1-palmitoylglycerophosphoinositol) pathways were lowered in tumors of PyMT/Sirt6 mice ([Figures 3](#fig3){ref-type="fig"}E, [S3](#mmc1){ref-type="supplementary-material"}E, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). Because PPP is an important source of NADPH for glutathione regeneration and reactive oxygen species (ROS) management, we assessed glutathione and ROS levels in cells with and without SIRT6 overexpression and found no differences between groups ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). Next, we asked whether expression of SIRT6-suppressed lipid metabolism genes is induced by PI3K signaling. Of note, expression of several of these genes was significantly lower in DLD-1-WT compared to DLD-1-MT cells ([Figure S4](#mmc1){ref-type="supplementary-material"}F), hence indicating that removal of the constitutive active PI3K mutation in otherwise isogenic cells suppresses expression of several lipid metabolism genes. Interestingly, a similar effect was observed by SIRT6 overexpression as mRNA content of these lipid metabolism genes was indistinguishable between DLD-1-MT cells overexpressing SIRT6 and DLD-1-WT cells ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Hence, these data suggest that suppression of lipid metabolism genes could be part of the mechanisms by which SIRT6 overexpression dampens CSCs. As many of these genes are implicated in fatty acid oxidation (FAO), we tested the effect of treatment with etomoxir (a clinically tested, specific FAO inhibitor) ([@bib11]). Interestingly, we found that treatment with etomoxir mimics the effect of SIRT6 overexpression as it minimally changed tumorsphere-forming capacity of SIRT6-insensitive cells while strongly reduced tumorsphere-forming capacity of SIRT6-sensitive cells ([Figure S4](#mmc1){ref-type="supplementary-material"}G). Also, combining etomoxir treatment with SIRT6 overexpression had sub-additional effect on tumorsphere-forming capacity of SIRT6-sensitive cells ([Figures S4](#mmc1){ref-type="supplementary-material"}G). Combined with data indicating that SIRT6 overexpression increases ATP content ([Figure S4](#mmc1){ref-type="supplementary-material"}H), our results indicate that FAO inhibition is unlikely to mediate the anti-CSCs action of SIRT6 overexpression; yet, our data suggest that similarly to enhanced SIRT6 action FAO inhibition could be used to dampen stemness of tumors bearing PI3K activation.

Our in vitro and in vivo data shown in [Figures S1](#mmc1){ref-type="supplementary-material"}A, [S2](#mmc1){ref-type="supplementary-material"}A, and [S4](#mmc1){ref-type="supplementary-material"}A strongly indicate that SIRT6 overexpression does not affect AKT phosphorylation; yet, it dampens expression of several PI3K-controlled genes and metabolites ([Figures 3](#fig3){ref-type="fig"}D, 3E, [S3](#mmc1){ref-type="supplementary-material"}D, and [S4](#mmc1){ref-type="supplementary-material"}C). Hence, to further explore the mechanism by which SIRT6 suppresses PI3K signaling, we investigated whether SIRT6 overexpression affects the PI3K signaling further downstream of AKT, that is at the transcriptional level. First, we focused on *GNA14*, *RPSK6A1*, *SQSTM1*, and *YWHAZ* because they are known PI3K-controlled genes ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Our data shown in [Figure 4](#fig4){ref-type="fig"}C strongly indicate that PI3K signaling induces their expression as *GNA14*, *RPSK6A1*, *SQSTM1*, and *YWHAZ* mRNA level was higher in DLD-1-MT compared to DLD-1-WT cells ([Figure 4](#fig4){ref-type="fig"}C). Of note, as it was the case for several PI3K-controlled genes involved in lipid metabolism ([Figure S4](#mmc1){ref-type="supplementary-material"}E), SIRT6 overexpression reduced expression of these genes in DLD-1-MT cells to level similar to DLD-1-WT cells while did not alter (or modestly increased) their expression in DLD-1-WT cells ([Figure 4](#fig4){ref-type="fig"}C). Next, we performed chromatin immunoprecipitation (ChIP) for SIRT6 in cancer cells overexpressing SIRT6 and their controls. Our results indicate that indeed SIRT6 binds to promoters of these PI3K-controlled genes and that SIRT6 overexpression increases SIRT6 binding to these promoters ([Figure 4](#fig4){ref-type="fig"}D). However, our ChIP assays for acetylated H3K9 and H3K56 (H3K9ac and H3K56ac) indicated that occupancy of H3K9ac and H3K56ac at these promoters was mainly increased (and not decreased as expected) by SIRT6 overexpression ([Figure 4](#fig4){ref-type="fig"}E) suggesting that the effect of SIRT6 overexpression on PI3K-controlled genes and potentially on cancer stemness is independent to SIRT6 histone deacetylase activity. To directly test this idea, we overexpressed a deacetylase inactive mutant of SIRT6 bearing a tyrosine instead of an aspartic acid at position 63 (D63Y) ([@bib19]) in SIRT6-sensitive cells. Because overexpression of SIRT6 or SIRT6 D63Y mutant exerted similar action on tumorsphere-forming capacity of these cells ([Figure 4](#fig4){ref-type="fig"}F), we concluded that SIRT6 overexpression suppresses PI3K signaling at the transcriptional level and exerts anti-tumorsphere-forming action via a mechanism independent to its histone deacetylase activity.

Discussion {#sec3}
==========

SIRT6 expression ([@bib19], [@bib40], [@bib47]) and cancer progression and stemness ([@bib30], [@bib29], [@bib32]) are clinically relevant; yet, whether one affects the other is unknown. Here, we provide both in vivo and in vitro evidence that enhanced SIRT6 suppresses cancer progression and stemness. Unexpectedly, this effect is not universal to all cancer types and appears to be independent of the histone deacetylase activity of SIRT6. Indeed, our data indicate that the status of PI3K activation is crucial for determining responsiveness to SIRT6 overexpression. Our transcriptomic and metabolomic results from PyMT-driven breast cancer in mice, as well as both in vitro and in vivo functional assays in human cancer cells with different levels of PI3K signaling, and our ChIP assays strongly indicate that SIRT6 thwarts cancer stemness, at least in part, by suppressing the PI3K pathway at the transcriptional level. While our findings are in keeping with previously published results indicating that SIRT6 negatively regulates PI3K signaling, they indicate that this effect is not dependent on the ability of SIRT6 to deacetylate histone 3 at lysine 9 and/or 56 at promoter regions of PI3K effector genes as previously suggested ([@bib46]). A deacetylase-independent action is not at odds with the fact that others have shown very minor histone deacetylase ability of SIRT6 ([@bib13], [@bib23]). As activation of PI3K signaling promotes survival of CSCs ([@bib10], [@bib14]), our data support a model whereby enhanced SIRT6 dampens PI3K signaling at the transcriptional level, an effect that leads to several changes, including altered glucose and lipid metabolism and reduced cancer stemness. Because SIRT6 overexpression dampens expression of a large number of genes, we suggest that its anti-cancer-stemness action is brought about by a concerted rather than a single mechanistic change. It is important to keep in mind that in addition to PI3K activation our results do not exclude the possibility that SIRT6 overexpression may influence behavior of tumors bearing other types of mutations. Hence, further analysis aimed at testing the effect of SIRT6 overexpression in a large panel of tumors bearing a wide range of different mutations is warranted.

Augmented SIRT6 function has been shown to bring about beneficial effects in the context of metabolism ([@bib1]) and aging ([@bib16]); thus, combined with results reported herein these data provide rationale for developing SIRT6 agonists as therapeutics for age-related diseases (e.g., cancer and diabetes). Furthermore, our findings are relevant in a personalized medicine context as they could be used to stratify patients bearing tumors with PI3K activation into likely responders to means aimed at increasing SIRT6 function.

Experimental Procedures {#sec4}
=======================

Mouse Generation and Studies {#sec4.1}
----------------------------

MMTV-PyMT mice were generated as previously described ([@bib9]). Sirt6BAC mice were generated by BAC transgenesis as described previously ([@bib1]) and are available from The Jackson Laboratory (JAX\#028361). Mice were housed in groups of four or five with food and water available ad libitum in light- and temperature-controlled environments. Care of mice was within the procedures approved by animal care and experimentation authorities of the Canton of Geneva, Switzerland.

SIRT6 Overexpression in Cancer Cells {#sec4.2}
------------------------------------

We produced recombinant retroviruses by transfecting Phoenix-Ampho cells (ATCC), using TransIT-293 transfection reagent (Mirus) and pBABE retroviral constructs. Cells were transfected with pBABE vectors expressing human-SIRT6, or deacetylase-dead human-SIRT6 bearing a tyrosine instead of an aspartic acid at position 63 (D63Y) ([@bib19]), or pBABE empty vector and selected for puromycin resistance.

In Vitro Assessment of Cell Proliferation {#sec4.3}
-----------------------------------------

Cells were fixed with formalin and stained with Crystal Violet (CV). Then, CV-stained cells were dissolved with 5% acetic acid for 30 min and 200 μL of this solution was transferred to a 96-well plate and read in a plate reader at 570 nm. T1 and T2 values were normalized to T0. Proliferation curves were compared between groups and experiments were repeated at least three times.

Tumorsphere Assays {#sec4.4}
------------------

Tumorsphere formation was induced in ultralow-adherent 6-well plates. Cells were plated at a density of 5,000 cells per well in triplicate in a 6-well plate in a 1% methylcellulose containing media (MammoCult supplemented with MethoCult media, STEMCELL Technologies). Tumorsphere formation was quantified 7 days after plating. Spheres with a diameter equal or higher than 50 μm were deemed tumorspheres. Etomoxir (Sigma) was added at the specified concentrations to the media. Experiments were repeated at least three times.

Mouse Xenograft Assay {#sec4.5}
---------------------

Cells were trypsinized, suspended in PBS, and injected subcutaneously into the flank of NOD/SCID mice. Cells were injected at the following numbers: 1 × 10^6^ and 1 × 10^4^ MCF10DCIS, 1 × 10^6^ MDA-MB-231, 1 × 10^5^ H1650, 1 × 10^5^ DLD-1 MT, and 1 × 10^5^ DLD-1 WT cells. Mice were checked twice a week for tumor appearance and tumor diameter measurements.

Tumor Grade Assessment {#sec4.6}
----------------------

Mice bearing at least one tumor with 10 mm of major diameter (as measured manually with a caliper) were sacrificed and all their detectable tumors collected. Tumors of comparable size were used for histologic analysis. Areas of different histological types (adenoma, hyperplasia, necrosis, and carcinoma) were assessed by surveying the whole tumor area as previously described ([@bib38]).

mRNA and Protein Contents {#sec4.7}
-------------------------

Mice were sacrificed, and tissues were quickly removed and snap-frozen in liquid nitrogen and subsequently stored at -- 80°C. RNAs were extracted using TRIzol reagent (Invitrogen). Complementary DNA was generated by Superscript II (Invitrogen) and used with SYBR Green PCR master mix (Applied Biosystems) for real-time qPCR analysis. mRNA contents were normalized to *β-actin* and/or *36B4* mRNA levels. All assays were performed using an Applied Biosystems QuantStudio 5 Real-Time PCR System. For each mRNA assessment, real-time qPCR analyses were repeated at least three times. Proteins were extracted by homogenizing samples in lysis buffer (Tris 20 mM, EDTA 5 mM, NP40 1% \[v/v\], protease inhibitors \[P2714-1BTL from Sigma\]) and then resolved by SDS-PAGE and finally transferred to a nitrocellulose membrane by electroblotting. Proteins were detected using commercially available antisera as previously described ([@bib33], [@bib34]).

ALDH Activity {#sec4.8}
-------------

ALDH activity was assessed using the ALDH Activity Colorimetric Assay Kit from Biovision (K731-100) and following the manufacturer's instructions. Briefly, samples were homogenized with 200 μL of ice-cold ALDH assay buffer, and 3 μL of the homogenate was used in the assay. Absorbance was measured at 450 nm every 5 min over 1 hr, and the oxidation of Acetaldehyde to NADH was calculated according to the manufacturer's instructions.

FACS {#sec4.9}
----

ALDH activity was measured in cancer cells using the Aldefluor kit following the manufacturer protocol. 5 × 10^5^ of H1650 or MCF10DCIS cells were incubated with Aldefluor reagent and N,N-diethylaminobenzaldehyde (DEAB; represented in blue) or Aldefluor reagent only (represented in red). After a 40-min incubation period, cells were analyzed by flow cytometry, and results were generated using FlowJo software. Values mentioned along with the graphs indicate percentage of cells with high ALDH activity.

Microarray and Metabolomic Assays {#sec4.10}
---------------------------------

Mice were sacrificed, and tissues were quickly removed, frozen in liquid nitrogen, and subsequently stored at --80°C. RNAs were extracted by QIAGEN mRNA extract kits (RNeasy plus). Microarray analyses were performed by University of Texas Southwestern Medical Center at Dallas microarray Core facility (<https://microarray.swmed.edu/>) using Illumina Chip Mouse WG-6 v.2.0 (Illumina). Metabolites contents were measured by Metabolon. The differential analysis of the transcriptomic and metabolomic data were performed using CyberT ([@bib2], [@bib18]). Briefly, the average signal intensity was transformed using a log base 2 normalization, and a regularized t test was then performed using Cyber-T with a window size of 51 and a Bayesian confidence value of 5. p values of 0.001 and 0.01 were considered significant for microarray and metabolomics analyses, respectively. Pathway and functional enrichment was carried out using DAVID ([@bib12]).

Chromatin Immunoprecipitation Assays {#sec4.11}
------------------------------------

ChIP assays were performed as previously described ([@bib20], [@bib40]). Antibodies used are 5 μL anti-SIRT6 (Abcam; ab62739), 5 μL anti-H3K9Ac (Millipore 07-352), and 5 μL anti-H3K56Ac (ab76307). Data were normalized to values obtained with unspecific immunoglobulin Gs (IgGs) (Abcam).

Determination of the Cellular Glutathione Content {#sec4.12}
-------------------------------------------------

Cells were seeded in 96-well plate at a density of 10^4^ per well and incubated (protected from the light) with 20 μM monobromobimane (mBBr) for 10 min at 37°C. The conjugation of glutathione with monobromobimane was followed by measuring the fluorescent product at Ex/Em 394/490 nm using SpectraMax Paradigm microplate reader (Molecular Devices). The results are expressed as a percentage of the glutathione content in control cells.

Determination of Mitochondrial ROS Content {#sec4.13}
------------------------------------------

5 × 10^4^ cells in Hank's balanced salt solution (HBSS), 10 mM HEPES (pH 7.4), 17.5 mM glucose, 1.55 mM CaCl~2~, and 10% FBS were incubated with 5 μM MitoSox (Thermo Fisher Scientific) for exactly 10 min at room temperature before analysis on a CyAn flow cytometer (Beckman Coulter).

ATP Determination in Tumorspheres {#sec4.14}
---------------------------------

Cells were lysed with 10% trichloroacetic acid × 30 min in ice. Next, the lysate was centrifuged at 13,000 rpm for 5 min at 4 degrees and a 1/16 dilution of the supernatant (in distillated ultrapure water) was used for ATP determination using a commercial kit (Molecular Probe \#A22066) according to the manufacturer's instructions. Values were normalized to lysate protein contents.

Dataset Compilation {#sec4.15}
-------------------

Datasets of stem cells (ESCs, ASCs, and iPS cells) and terminally differentiated tissues (TDTs) was generated by compiling 246 whole-genome microarray datasets downloaded form ArrayExpress database (<https://www.ebi.ac.uk/arrayexpress/>). In order to avoid inter-platform biases, only data generated using the same microarray platform (Affimetrix 430 2.0) were selected. Microarrays were downloaded as raw files, concatenated in a unique dataset and normalized according to the Robust Multichip Average (RMA) algorithm.

Statistical Analyses {#sec4.16}
--------------------

Data are reported as mean ± SEM. Statistical analyses were performed using GraphPad Prism 6.0c software. Unpaired two-tailed t tests were employed when two groups were compared, and one-way ANOVA with Tukey correction for multiple comparisons was used when three or more groups were compared unless otherwise specified.
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![SIRT6 Thwarts Stemness and Tumorigenic Capacity of Human Cancer Cells with PI3K Activation\
(A and B) Proliferation (A) and tumorsphere-forming capacity (B) of indicated cells harboring empty vector (Ctrl) or a vector overexpressing human SIRT6 (Sirt6).\
(C) Kaplan-Meier curves comparing percentage of tumor-free mice at different times after subcutaneous injection of indicated cells harboring empty vector (Ctrl) or a vector overexpressing human SIRT6 (Sirt6).\
(D) Known mutational status of indicated cancer cells.\
In (A) and (B), ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (two-tailed unpaired Student's t test). Error bars represent SEM. In (C), ^∗^p \< 0.05, ^∗∗^p \< 0.01 (long-rank test). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![SIRT6 Overexpression Hinders Progression of PyMT-Driven Breast Cancer in Mice\
(A) Immunoblot image and quantification of SIRT6 level normalized to β-Actin content in tumors of 12- to 14-week-old PyMT and PyMT/Sirt6 mice.\
(B and C) mRNA levels of *Sirt6* (B) and of PyMT (C) normalized to *β-Actin* mRNA content in tumors of 12- to 14-week-old PyMT (n = 7) and PyMT/Sirt6 (n = 8) mice.\
(D) Gene set enrichment analysis (GSEA) plot showing the enrichment score (ES) of SIRT6's target genes as indicated in table S2 of Kawahara and colleagues ([@bib17]). Gene microarray was performed using RNA extracted from tumors of 12- to 14-week-old PyMT (n = 6) and PyMT/Sirt6 (n = 6) mice.\
(E) Tumor volume, weight, and number per mouse in 12-week-old PyMT (n = 18) and PyMT/Sirt6 (n = 18) mice.\
(F) Diameter evolution over time of tumors in PyMT and PyMT/Sirt6 mice.\
(G) Representative images of tumors stained with H&E (scale bar, 100 μm) and percentage of area of necrosis, adenoma, hyperplasia, and carcinoma in similar-size tumors from PyMT and PyMT/Sirt6 mice (n = 9--10 per group). Scoring of necrosis, adenoma, hyperplasia, and carcinoma was performed on whole tumor area of H&E-stained tissues.\
(H) Expression profile of normal mammary epithelial markers using microarray data as in (D).\
In (A)--(H), ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001 (two-tailed unpaired Student's t test). Error bars represent SEM. In (D), FDR, false discovery rate q value. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![SIRT6 Hinders Stemness of PyMT-Driven Breast Tumors in Mice\
(A and B) Enrichment of genes downregulated in PyMT/Sirt6 compared to PyMT tumors were tested in a cohort of public available whole-genome microarrays.\
(C) ALDH activity was measured in tumors from 12- to 14-week-old PyMT (n = 6) and PyMT/Sirt6 (n = 6) mice.\
(D) Gene set enrichment analysis (GSEA) plot showing the enrichment score (ES) of PI3K's target genes. Gene microarray was performed using RNA extracted from tumors of 12- to 14-week-old PyMT (n = 6) and PyMT/Sirt6 (n = 6) mice.\
(E) Pathway enrichment analysis of differentially accumulated metabolites in PyMT/Sirt6 compared to PyMT tumors (n = 6/group). Statistical analysis was done using paired t test between the average values across the samples of each experimental group (PyMT versus PyMT/Sirt6). ^∗^p \< 0.05, ^∗∗^p \< 0.01.\
In (A), (B), and (D), FDR represents false discovery rate q value. In (C), Error bars represent SEM. ^∗^p \< 0.05 (two-tailed unpaired Student's t test). See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.](gr3){#fig3}

![PI3K Activation Is Required for Anti-cancer Stemness Action of SIRT6 Overexpression\
(A) Tumorsphere-forming capacity of indicated cells harboring empty vector (Ctrl) or a vector overexpressing human SIRT6 (Sirt6).\
(B) Kaplan-Meier curves comparing percentage of tumor-free mice at different times after subcutaneous injection of indicated cells harboring empty vector (Ctrl) or a vector overexpressing human SIRT6 (Sirt6).\
(C) mRNAs levels of PI3K-controlled genes in DLD-1 WT and MT cells harboring empty vector (Ctrl) or a vector overexpressing human SIRT6 (Sirt6).\
(D and E) ChIP analysis of SIRT6 (D) and of H3K9ac and H3K56ac (E)on gene promoters in DLD-1 MT cells (in D and E, the data are expressed relative to Ctrl).\
(F) Tumorsphere-forming capacity of DLD-1 MT cells harboring empty vector (Ctrl), a vector overexpressing human SIRT6 (Sirt6) or a vector overexpressing a deacetylase inactive mutant of SIRT6 (Sirt6-D63Y). Error bars represent SEM.\
In (A), (D), and (E), ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001 (two-tailed unpaired Student's t test). In (B), ^∗∗^p \< 0.01, long-rank test. In (C) and (F), ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001 (one-way ANOVA). See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
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